Year: 2026
Type: preprint
Abstract: Caspase recruitment domain-containing protein 9 (CARD9) is an important adaptor protein of the innate immune responses to various fungal pathogens, including Pneumocystis species. CARD9 signaling is paramount in Pneumocystis pneumonia (PCP) host defense, and excessive inflammatory responses driven by this molecule can promote deleterious lung injury. We previously demonstrated that BRD5529, a first generation small-molecule CARD9 inhibitor, attenuates pulmonary inflammatory cytokine production during PCP. Here, we investigated the previously unreported effects of BRD5529 on Pneumocystis murina burden in vivo and in an ex vivo PCP-infected precision-cut lung slice (PCLS) model. In vitro, BRD5529 treatment (1 mg/kg) reduced lung organism burden in mice with established PCP, with an effect similar in magnitude to standard-of-care trimethoprim-sulfamethoxazole (TMP-SMX) therapy. In infected PCLS cultured with BRD5529 for 72 h, P. murina viability was also reduced, with the greatest reduction observed at lower BRD5529 concentrations. BRD5529 treatment did not reduce PCLS metabolic activity and viability after 72 h, as assessed by resazurin reduction. Together, these findings suggest that pharmacological CARD9 inhibition may impact organism burden/viability in addition to reducing lung inflammation during PCP.
Authors: Jenna L McLean, Theodore Kottom, Andrew Limper
Institution: Mayo Clinic
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Institutes of Health
OpenAlex ID: W7237230930
